Importantly, BRD9 inhibition limited the input of glucose into the PPP, confined antioxidant activity, disrupted mitochondrial respiration, and strongly impaired PCa progression, thus serving as a promising target for clinical treatment. Here, BRD9 is linked to posterior cortical atrophy.